President Donald Trump's choice to lead the U.S. Patent and Trademark Office is two-thirds of the way to being uncontroversial.

Irell & Manella managing partner Andrei Iancu got support over the weekend from the Innovation Alliance, a lobbying group that generally supports patent holder rights, and on Monday from United for Patent Reform, whose membership includes many big tech industry players that usually prefer more limited patent rights.

That leaves the biotech and pharmaceutical sector, where Iancu may have to smooth over some unease based on his role last year in a case that resulted in a Federal Circuit decision that was favorable for his client but deeply unpopular with biotech firms.